Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-Taxel: Bevacizumab + Paclitaxel + Capecitabine in TNBC
NCT01069796Phase 2Terminated
- Sponsor
- ARCAGY
- Start
- Apr 2010
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative metastatic breast cancer (mTNBC), breast cancer, sponsored by ARCAGY. Started Apr 2010; status: terminated.
02
Drugs
bevacizumab
03
Conditions
triple-negative metastatic breast cancer (mTNBC)breast cancer
Beyond the preview
Go deeper on NCT01069796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069796.